Dutasteride 0.5 mg vs Placebo: Number of Participants With Post-biopsy Macroscopic Hematuria

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measure	Value	95% interval, lower	95% interval, upper	Method	Source
Risk in group 1	0.0314	0.0264	0.0372	wilson	ClinicalTrials.gov
Risk in group 2	0.0412	0.0356	0.0478	wilson	ClinicalTrials.gov
Risk difference, group 1 minus group 2	-0.00988	-0.0181	-0.00174	newcombe hybrid score	ClinicalTrials.gov
Risk ratio, group 1 over group 2	0.76	0.606	0.954	log	ClinicalTrials.gov
Odds ratio, group 1 over group 2	0.753	0.595	0.952	log	ClinicalTrials.gov
Number needed to treat, for one fewer participant with the outcome on Dutasteride 0.5 mg than on Placebo	101	55.3	575	from the risk difference interval	ClinicalTrials.gov

Groups 2

Group 2 names the comparator: placebo.

Group	Title	Description	With the outcome	Analysed	ClinicalTrials.gov code	Source
Group 1	Dutasteride 0.5 mg	Dutasteride 0.5 milligrams (mg), repeat oral once daily dosing for 4 years. Dutasteride supplied as gelatin capsule.	127	4,049	OG001	ClinicalTrials.gov
Group 2	Placebo	Placebo, repeat oral once daily dosing for 4 years. Placebo supplied as matching dutasteride capsules.	168	4,073	OG000	ClinicalTrials.gov

Outcome 5

Field	Value	Source
Type	SECONDARY	ClinicalTrials.gov
Title	Number of Participants With Post-biopsy Macroscopic Hematuria	ClinicalTrials.gov
Description	Participants reported events of macroscopic hematuria (visible blood in the urine) throughout the study.	ClinicalTrials.gov
Time frame	Baseline to Year 4	ClinicalTrials.gov
Population	Efficacy Population	ClinicalTrials.gov

Trial 8

Field	Value	Source
Title	"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk	ClinicalTrials.gov
NCT number	NCT00056407	ClinicalTrials.gov
Phases	PHASE3	ClinicalTrials.gov
Conditions	Neoplasms, Prostate	ClinicalTrials.gov
Interventions	Dutasteride, Placebo	ClinicalTrials.gov
Lead sponsor	GlaxoSmithKline	ClinicalTrials.gov
Results first posted	2010-03-05	ClinicalTrials.gov
Results on ClinicalTrials.gov	https://clinicaltrials.gov/study/NCT00056407?tab=results	ClinicalTrials.gov

Source 4

Field	Value	Source
Release	trial-comparisons-2026-03-23-0.1.0	ClinicalTrials.gov
Release manifest SHA-256	f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57	ClinicalTrials.gov
AACT copy	2026-03-23	ClinicalTrials.gov
Tables read	outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet	ClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.